Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to macroalbuminuria Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in eGFR · preventing the progression of CKD
1 finding from 1 review
All‐cause death ( · preventing the progression of CKD
It is very uncertain whether metformin changes all‐cause death ( compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Withdrew due to intolerance ( · preventing the progression of CKD
Metformin probably leads to higher withdrew due to intolerance ( compared with placebo (moderate certainty).
1 finding from 1 review
Dose tolerability ( · preventing the progression of CKD
1 finding from 1 review
Kidney failure · preventing the progression of CKD
It is very uncertain whether metformin changes kidney failure (median compared with placebo (very low certainty).
1 finding from 1 review
Change in proteinuria (1 year) · preventing the progression of CKD
1 finding from 1 review
3P‐MACE median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 3P‐MACE median compared with placebo (moderate certainty).
1 finding from 1 review
4P‐MACE median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 4P‐MACE median compared with placebo (moderate certainty).
1 finding from 1 review
Kidney composite outcome median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney composite outcome median compared with placebo (high certainty).
1 finding from 1 review
Kidney failure · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney failure median compared with placebo (high certainty).
1 finding from 1 review
Hypoglycaemia requiring third‐party assistance median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower hypoglycaemia requiring third‐party assistance median compared with placebo (high certainty).
1 finding from 1 review
Diabetic ketoacidosis median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to higher diabetic ketoacidosis median compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic, culture‐verified UTI Women with recurrent UTI · preventing UTI
Any cranberry product probably leads to lower symptomatic, culture‐verified UTI Women with recurrent UTI compared with placebo or control (moderate certainty).
1 finding from 1 review